Patents by Inventor Claus Munck Petersen
Claus Munck Petersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170158766Abstract: The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.Type: ApplicationFiled: February 15, 2017Publication date: June 8, 2017Applicant: H. Lundbeck A/SInventors: Anders Nykjaer, Claus Munck Petersen
-
Patent number: 9605073Abstract: The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.Type: GrantFiled: February 13, 2015Date of Patent: March 28, 2017Assignee: H. Lundbeck A/SInventors: Anders Nykjaer, Claus Munck Petersen
-
Publication number: 20160349276Abstract: The present invention relates to the use of Sortilin as a biomarker. In particular, Sortilin is useful as a biomarker for affective disorders. In one aspect of the invention Sortilin may be used to aid the diagnosing and to monitor disease progression in bipolar disorder and unipolar depression by measuring Sortilin levels. The invention further provides methods for informing the choice of treatment of bipolar disorder and unipolar depression by determining the levels of Sortilin.Type: ApplicationFiled: February 6, 2015Publication date: December 1, 2016Applicant: H. Lundbeck A/SInventors: Jesper Lundhede Jepsen, Anders Nykjær, Niels Peter Ole Mors, Claus Munck Petersen, Søren Dinesen Østergaard, Simon Glerup
-
Publication number: 20150239973Abstract: The present invention relates to a method to increase the survival of neurons by modulating the interaction between Sor LA and GDNF-family ligand receptors. The agent used to modulate the interaction between the SorLA and GDNF-family ligand receptors are selected from proteins, peptides, antibodies or small organic compounds. The invention also relates to a pharmaceutical compositions comprising these agent as well as the use of said agent or pharmaceutical composition in the treatment of a disease associated with the loss of neurons and/or wherein the survival of neurons are desired.Type: ApplicationFiled: April 8, 2015Publication date: August 27, 2015Applicant: H. LUNDBECK A/SInventors: Anders Nykjær, Simon Glerup, Peder Søndergaard Madsen, Claus Munck Petersen, Ditte Olsen
-
Publication number: 20150232565Abstract: The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.Type: ApplicationFiled: February 13, 2015Publication date: August 20, 2015Applicant: H Lundbeck A/SInventors: Anders Nykjaer, Claus Munck Petersen
-
Patent number: 8986690Abstract: The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.Type: GrantFiled: May 27, 2011Date of Patent: March 24, 2015Assignee: H. Lundbeck A/SInventors: Anders Nykjaer, Claus Munck Petersen
-
Patent number: 8815808Abstract: The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.Type: GrantFiled: October 5, 2011Date of Patent: August 26, 2014Assignee: H. Lundbeck A/SInventors: Anders Nykjaer, Claus Munck Petersen
-
Publication number: 20130164297Abstract: The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.Type: ApplicationFiled: May 27, 2011Publication date: June 27, 2013Applicant: H. Lundbeck A/SInventors: Anders Nykjaer, Claus Munck Petersen
-
Publication number: 20130115212Abstract: The present invention relates to a method to increase the survival of neurons by modulating the interaction between SorLA and GDNF-family ligand receptors. The agent used to modulate the interaction between the SorLA and GDNF-family ligand receptors are selected from proteins, peptides, antibodies or small organic compounds. The invention also relates to a pharmaceutical compositions comprising these agent as well as the use of said agent or pharmaceutical composition in the treatment of a disease associated with the loss of neurons and/or wherein the survival of neurons are desired.Type: ApplicationFiled: June 14, 2011Publication date: May 9, 2013Applicant: LUNDBECK A/SInventors: Anders Nykjær, Simon Glerup, Peder Søndergaard Madsen, Claus Munck Petersen, Ditte Olsen
-
Patent number: 8377701Abstract: The present invention provides a Sortilin crystal and methods for growing said crystal. The invention furthermore provide methods for design of specific ligands based on the crystal structure of Sortilin. The present invention also relates to the preparation and use of such ligands for the preparation of a medicament for the treatment of disease, damage or disorders of the central and peripheral nervous systems.Type: GrantFiled: April 27, 2009Date of Patent: February 19, 2013Assignee: H. Lundbeck A/SInventors: Jens Claus Munck Petersen, Poul Nissen, Peder Søndergaard Madsen, Esben Meldgaard Høgh Quistgaard, Morten Keller Grøftehauge, Søren Skou Thirup, Jacob Flyvholm Cramer, Jacob Lauwring Andersen
-
Publication number: 20120082671Abstract: The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.Type: ApplicationFiled: October 5, 2011Publication date: April 5, 2012Applicant: H. Lundbeck A/SInventors: Anders Nykjaer, Claus Munck Petersen
-
Patent number: 8066997Abstract: The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.Type: GrantFiled: December 19, 2003Date of Patent: November 29, 2011Inventors: Anders Nykjaer, Claus Munck Petersen
-
Publication number: 20110166032Abstract: The present invention provides methods for design and identification of Vps10p domain receptor specific molecular imaging ligands based on the atomic coordinates of said Vps10p-domain. The present invention also relates to the preparation and use of such ligands for the preparation of a target specific imaging reagent or molecular imaging probe useful in detection of said Vps10p-domain receptor involved in disease.Type: ApplicationFiled: April 27, 2009Publication date: July 7, 2011Applicant: H. LUNDBECK A/SInventor: Jens Claus Munck Petersen
-
Publication number: 20110160439Abstract: The present invention provides a Sortilin crystal and methods for growing said crystal. The invention furthermore provide methods for design of specific ligands based on the crystal structure of Sortilin. The present invention also relates to the preparation and use of such ligands for the preparation of a medicament for the treatment of disease, damage or disorders of the central and peripheral nervous systems.Type: ApplicationFiled: April 27, 2009Publication date: June 30, 2011Applicant: H. LUNDBECK A/SInventors: Jens Claus Munck Petersen, Poul Nissen, Peder Søndergaard Madsen, Esben Meldgaard Høgh Quistgaard, Morten Keller Grøftehauge, Søren Skou Thirup, Jacob Flyvholm Cramer, Jacob Lauwring Andersen